The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Cardiac arrest is a leading cause of sudden death, but the survival rate of cardiac arrest is
only 5-35%.
Although, the first resuscitation of cardiac arrest patient would be success, the hypoxic
brain injury after cardiac arrest is an important cause of the mortality and the morbidity.
For the management of the hypoxic brain injury after cardiac arrest, American Heart
Association and European Resuscitation Council recommend induced mild hypothermia therapy.
And, ILCOR(International Liaison Committee on Resuscitation) announced the standard treatment
of post cardiac arrest syndrome(the success state of first resuscitation of the cardiac
arrest patient) included the induced mild hypothermia therapy at September, 2008.
The generalized seizure and myoclonus arise in over 60% of post cardiac arrest syndrome
patients and they are very difficult to control. Also, the occurrence of them implies poor
prognosis of the patient.
Although, mild hypothermia therapy could be decrease the development and propagation of
generalized seizure and myoclonus theologically, the therapy could not prevent the
development and propagation of them entirely. Therefore, the use of prophylactic
anticonvulsant should be needed. But, there is not randomized control study about the use of
prophylactic anticonvulsant.
We hypothesized that the use of prophylactic anticonvulsant to post cardiac arrest syndrome
patients would decrease the rate of occurrence of generalized seizure and myoclonus and would
improve the neurologic outcome.
We planed that we used two anti-epileptic drugs - valproate, clonazepam - for the
prophylactic anticonvulsant. The valproate and clonazepam are in general use for prevention
and treatment of generalized seizure and myoclonus and are recommended to treat of
generalized seizure and myoclonus to post cardiac arrest syndrome patients by 2008 guideline
of ILCOR.